Despite their adequate immunologic response to ART, these individuals had, after reaching a CD4 cell count above 500 cells/μl, double the risk of progression to the study’s primary endpoint (serious AIDS events, serious non-AIDS events or death) compared to those who started treatment prior to their CD4 declining below 500 cells/μl. The gene discussed is CD4; the disease is AIDS.